Bivalirudin/Prasugrel Versus Abciximab/Clopidogrel in Patients Presenting With STEMI

• Status: Unknown status
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

In the setting of ST elevation myocardial infarction newer therapies has been recently studied and, following encouraging results, introduced into the clinical practice. Prasugrel showed to be a valid alternative to overcome limitation of clopidogrel therefore providing a better ischemic protection. On the other hand, bivalirudin is at least as beneficial as heparin/abciximab as anticoagulant agent but associated with fewer hemorrhagic events. The primary hypothesis of the study is that the combination of prasugrel plus bivalirudin can be associated with a better risk/benefit profile.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Istituto Clinico Sant'Ambrogio
• Collaborators: Azienda Ospedaliera Niguarda Cà Granda; Centro Cardiologico Monzino; Istituto Clinico Humanitas
• Treatments: Abciximab; Antibodies, Monoclonal; Anticoagulants; Bivalirudin; Clopidogrel; Hirudins; Immunoglobulin Fab Fragments; Prasugrel Hydrochloride; Ticlopidine

Criteria

Inclusion Criteria:

• ST elevation myocardial infarction

• No contraindication to primary PCI

Exclusion Criteria:

• Known intolerance/allergy to one of the study drugs or their components

• Clinical indication to treatment with oral anticoagulant, including use of warfarin or dabigatran or other oral anticoagulant agents